TABLE 8.
BTK mutations in four zanubrutinib‐progressive patients
| Patient | Indication | Study day at disease progression | BOR by investigator | BTK mutation (VAF) |
|---|---|---|---|---|
| 101 016 | FL | Day 162 | PR | L528W (5.66%) |
| 102 004 | WM | Day 336 | Stable disease | C481S (9.95%) |
| 102 002 | CLL | Day 672 | PR |
C481S with 1442G > C (44.4%) C481S with 1441 T > A (6.7%) |
| 102 006 | CLL | Day 1345 | PR‐L |
C481S with 1442G > C (30.5%) C481S with 1441 T > A (16.0%) C481R with 1441 T > C (14.8%) L528W with 1583 T > G (8.2%) |
Abbreviations: BOR, best overall response; BTK, Bruton tyrosine kinase; CLL, chronic lymphocytic leukaemia; FL, follicular lymphoma; PR, partial response; PR‐L, partial response with lymphocytosis; VAF, variant allele frequency; WM, Waldenström's macroglobulinaemia.